phosphorylcholine has been researched along with Breast Neoplasms, Male in 1 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Breast Neoplasms, Male: Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 9.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 5.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clive, S | 1 |
| Gardiner, J | 1 |
| Leonard, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer[NCT04138342] | Phase 1 | 30 participants (Anticipated) | Interventional | 2019-09-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Breast Neoplasms, Male
| Article | Year |
|---|---|
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Br | 1999 |